The world’s largest medtech pureplay, Medtronic, believes drug-filled stents will be a major advance in coronary stent technology, which is why it is bypassing bioabsorable technologies like Abbott’s Absorb BVS stent and planning its next steps toward bringing DFSs to market.
The world’s largest medtech pureplay, Medtronic, believes drug-filled stents will be a major advance in coronary stent technology, which is why it is bypassing bioabsorable technologies like Abbott’s Absorb BVS stent and planning its next steps toward bringing DFSs to market.
Medtronic’s strategy is supported by positive early data from the RevElution trial of its DFS. Preliminary optical coherence tomography results,
Communication with patients has become a particularly crucial factor for investors, payers, and other healthcare decision-makers in a hostile market environment.
Out-of-hospital cardiac arrest remains one of the most challenging and resource-intensive emergencies in cardiovascular care. At SCAI 2025, clinicians presented a novel algorithm that improved triage decisions and reduced unnecessary interventions.
A battle may be forming over the 2027 FDA user fee reauthorizations. At a conference Friday, Democratic Rep. Jake Auchincloss supports them for their effectiveness, while Deputy FDA Commissioner Grace Graham echoed criticisms from HHS Sec. Kennedy, among others, in calling for reform to ensure public trust.
